Targeting Phage & Antibiotic Resistance 2018 May 17-18, 2018 Page 2
|
|
|
- Bertha Hall
- 6 years ago
- Views:
Transcription
1
2 Targeting Phage & Antibiotic Resistance 2018 May 17-18, 2018 Page 2
3 Day 1 May 17, h30 8h55 Registration & welcoming of attendees Badges & Abstracts book Distribution Opening Ceremony 9h00 General Introduction: How to overcome and combat antibiotic resistance in 2018? Session 1: Phage Therapy 2018: recent advances & challenges 9h20 9h45 10h10 Fighting multi-drug resistant Klebsiella pneumoniae by using lytic phages Marco Maria D Andrea, Università di Siena, Italy Control of catheter associated biofilms through efflux inhibition Brian Jones, Queen Victoria Hospital NHS Foundation Trust, United Kingdom Impact of virulent bacteriophages on vibrio cholerae infection and their use in preventing cholera Minmin Yen, Tufts University, USA 10h35 11h20 11h45 12h10 Lytic bacteriophages in the treatment of biofilm-forming bacteria involved in prosthetic joint infections Mariagrazia Di Luca, Charité Universitätsmedizin Berlin Hospital, Germany Microencapsulation of purified bacteriophages for targeted therapeutic applications Danish Malik, Loughborough University, United Kingdom Direct phenotypic screening to identify new antimicrobial agents Mark Sutton, National Infections Service, Public Health England, United Kingdom 12h35 Lunch Break, Poster & Exhibition Session 14h00 14h25 Development of infection-responsive surface coatings for bacteriophage delivery in the catheterised urinary tract Scarlet Milo, Queen Victoria Hospital NHS Foundation Trust, United Kingdom Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection Robert T. Schooley, University of California, USA Targeting Phage & Antibiotic Resistance 2018 May 17-18, 2018 Page 3
4 14h50 Among Short Oral Presentations already selected: Selection and characterisation of phages able to degrade biofilm produced by clinical isolates of E.faecalis Pasquale Marmo, University of Roma Tor Vergata, Italy State-of-the-art of modeling in vivo dynamics of naturally-occurring phages and in vivo dynamics of therapeutic phages Victoriya Volkova, Kansas State University, USA Bacteriophage therapy and urinary tract infections Tamara Perepanova, S.R. Institute of Urology and Interventional Radiology, Russia Safe & active sustained release of phages in gastro-intestinal tract Farzaneh Moghtader, Hacettepe University, Turkey Mycobacteriophage based platforms to discover drug targets for mycobacteria Sujoy Das Gupta, Bose Institute, India Efficient in vivo phage therapy via immunological cloaking Yoon Sung Nam, Korea Advanced Institute of Science & Technology, Korea 15h30 16h15 Short Oral Presentations Part 2 (7 minutes for presentation + 3 minutes for questions) Use of a biologtm system for monitoring and overcoming phage and antibiotic resistance during the treatment of MDR infections in humans Biswajit Biswas, Biological Defense Research Directorate, USA 17h45 20h00 End the first day Targeting Phage & Antibiotic Resistance 2018 Dinner You can register online before May 2. Targeting Phage & Antibiotic Resistance 2018 May 17-18, 2018 Page 4
5 Day 2 May 18, h55 Opening of the second day Session 2: Innovations against antibiotic resistance Focus on the new generation of antibiotics Focus on the strategic role of microbiota to overcome antibiotic resistance 9h00 9h25 9h50 10h15 Antimicrobial discovery from extreme halophiles Brendan Gilmore, Queen s University Belfast, United Kingdom General overview on the transmission of multidrug-resistant Mycobacterium tuberculosis Qian Gao, Fudan University, China Microarray patches for prevention and treatment of infectious diseases and their potential for reducing antibiotic resistance Ryan Donnelly, Queen s University Belfast, United Kingdom Reincarnation of a staphylococcal pathogenicity island as an antibacterial drone Richard Novick, New York University, USA 10h40 11h15 Inhibition of Shikimate kinase from M. Tuberculosis and H. Pylori for antibiotic discovery Concepción González-Bello, Universidade de Santiago de Compostela, Spain 12h45 Lunch Break, Poster & Exhibition Session Session 3: Special Session for Industrials: Innovations & Perspectives 14h00 17h00 This session is dedicated only to industrials, pharma companies, biotech and start-ups, to showcase their innovations. Phage-based antimicrobials: novel approaches for managing drug-resistant bacteria Alexander Sulakvelidze, Intralytix, USA Novel phage based therapeutics to address antibiotic resistance Naomi Zak, Biomx, United Kingdom 16h00 16h30 17h15 Round Table Discussion & Concluding Remarks Targeting Phage & Antibiotic Resistance 2018 Awards 17h30 End of Targeting Phage & Antibiotic Resistance 2018 Targeting Phage & Antibiotic Resistance 2018 May 17-18, 2018 Page 5
Bacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections
Bacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections November 7, 2017 NYSE MKT: APHB Safe Harbor Statement This presentation contains forward-looking statements that involve risks,
Diagnostics gathering intelligence to fight antimicrobial resistance
Diagnostics gathering intelligence to fight antimicrobial resistance Arjon van Hengel European Commission DG Research and Innovation, Health Directorate Unit "Fighting Infectious Diseases and Advancing
Phage therapy. Institute of Molecular Biomedicine Comenius University, Faculty of Medicine
Phage therapy Institute of Molecular Biomedicine Comenius University, Faculty of Medicine www.imbm.sk tothova.lubomira@gmail.com Outline Introduction Taxonomy Cycles of phages Bacterial resistance Phage
Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852
May 24, 2012 Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 Re: Comments on Docket #FDA- 2012 D 0148; Draft Guidance for Industry
The role of PHE s AMRHAI Reference Unit
The role of PHE s AMRHAI Reference Unit Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright What does AMRHAI offer? Susceptibility
Disarming Bacterial Virulence. Professor Roy Michael Robins-Browne
Disarming Bacterial Professor Roy Michael Robins-Browne DISARMING BACTERIAL VIRULENCE With antibiotic resistance rapidly emerging among many important bacterial pathogens, it is imperative that new classes
Antimicrobial Surfaces to Prevent Healthcare-Associated Infection
Antimicrobial Surfaces to Prevent Healthcare-Associated Infection Matthew P. Muller, MD, PhD, FRCPC Medical Director, Infection Prevention and Control, St. Michael s Hospital Chair, Provincial Infectious
Probiotics Health and Nutraceuticals
IPN-2016 II International Summit on Probiotics Health and Nutraceuticals September 07-09, 2016 Baltimore, USA About IPN-2016 "Join us, discuss and be a part in making healthier world" International summit
Funding AMR research: the UK Research Councils John Savill
Funding AMR research: the UK Research Councils John Savill Medical Research Council - UK MRC mission Encourage and support high-quality research with the aim of improving human health. Produce skilled
Assembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
Patentability/Literature Research
Patentability/Literature Research The probiotic-based solution to combat cholera as presented here comprises of two major innovative components: (1) the metabolite-dependent pathogen inhibition by a probiotic
Show Schedule 2017/2018
Show Schedule 2017/2018 exhibitors@selectbio.com +44 (0)1787 275642 Woodview, Bull Lane, SUDBURY, CO10 0FD, UK SELECTBIO.com 1 WELCOME Dear Colleague SELECTBIO is pleased to bring you our show schedule
Metallo-β-lactamase (MBL) project: From molecular biology to the development of an MBL-inhibitor
Metallo-β-lactamase (MBL) project: From molecular biology to the development of an MBL-inhibitor Indo-Norwegian Workshop on Antimicrobial Resistance Tromsø, Norway 26-27 th of September 2013 Ørjan Samuelsen
DNA: THE GENETIC MATERIAL
DNA: THE GENETIC MATERIAL This document is licensed under the Attribution-NonCommercial-ShareAlike 2.5 Italy license, available at http://creativecommons.org/licenses/by-nc-sa/2.5/it/ 1. Which macromolecule
Pathogenic Microorganism in Food. Marlia Singgih Wibowo School of Pharmacy ITB
Pathogenic Microorganism in Food Marlia Singgih Wibowo School of Pharmacy ITB Food Microbiology Analysis Microbiological analysis is important to determine the safety and quality of food. For many years,
SYMBIOTIC HEALTH. Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics
SYMBIOTIC HEALTH Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics Contact: Gerard Honig PhD, Director ghonig@symbioticbio.com Overview Biotechnology startup
Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant.
Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant tuberculosis Policy statement March 2010 1 Contents Abbreviations Executive summary 1.
Eliava Institute experience in phage research and therapy. G. Eliava Institute of Bacteriophages, Microbiology and Virology Tbilisi, Georgia
Eliava Institute experience in phage research and therapy G. Eliava Institute of Bacteriophages, Microbiology and Virology Tbilisi, Georgia Bacteriophages Bacteriophages are viruses that destroy bacterial
13 th Annual Microbial Sciences Symposium
13 th Annual Microbial Sciences Symposium April 16, 2016 Knafel Gymnasium Radcliffe Institute for Advanced Studies Harvard University Cambridge, MA Microbial Sciences Initiative at Harvard Introduction
Biofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement
Biofilm Protocol Optimization For Pseudomonas aeruginosa Culture Media, Incubation Time, and Biofilm Measurement Introduction In addition to the conventional arsenal of antibiotic resistance mechanisms
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP).
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP). Antonio D'Avolio, Marco Siccardi, Lorena Baietto, Marco Simiele, Silvia
Prevention of Transmission of the Superbug Carbapenem-Resistant Enterobacteriaceae (CRE) during Gastrointestinal Endoscopy
Prevention of Transmission of the Superbug Carbapenem-Resistant Enterobacteriaceae (CRE) during Gastrointestinal Endoscopy Sponsored by: Presentation by: Lawrence F. Muscarella, Ph.D. President LFM Healthcare
Microbial Biotechnology agustin krisna wardani
Microbial Biotechnology agustin krisna wardani 1. The Structure of Microbes Microbes (microorganisms) are tiny organisms that are too small to be seen individually by the naked eye and must be viewed with
number Done by Corrected by Doctor Hamed Al Zoubi
number 3 Done by Neda a Baniata Corrected by Waseem Abu Obeida Doctor Hamed Al Zoubi Note: it is important to refer to slides. Bacterial genetics *The main concepts we will talk about in this lecture:
Nordic Flow Cytometry Meeting
Nordic Flow Cytometry Meeting 30 31 August and 1 September 2017 Copenhagen, Denmark REGISTRATION Registration to the Nordic Flow Cytometry Meeting starts in December 2016 and includes access to all the
Tuberculosis Drug Accelerator
Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking
HCERES report on research unit:
Research units HCERES report on research unit: Thérapeutiques Cliniques et Expérimentales des Infections Under the supervision of the following institutions and research bodies: Université de Nantes Evaluation
GSK DDW Tuberculosis DPU portfolio. TB DPU, Tres Cantos GSK DDW
GSK DDW Tuberculosis DPU portfolio TB DPU, Tres Cantos GSK DDW TB DPU Global portfolio of Projects: GSK+ External Collaborations HTS/MTS Hit2Lead Lead Op Pre-Clincal FTIM Phase IIa Mtb KasA HTS/ELT/FBDD
Vecchi anticorpi per nuove terapie biologiche
Vecchi anticorpi per nuove terapie biologiche Rita De Santis PhD Head Biotech Products, R&D rita.desantis@sigma-tau.it Alfasigma headcounts 6% 24% 49% 3500 3033 22% 3000 2500 1177 Sales Force Manufacturing
UPDATE ON COMBACTE STATUS AND ACTIVITIES
UPDATE ON COMBACTE STATUS AND ACTIVITIES MARC BONTEN APRIL 24TH, 2017 Program 18:30-18:50 Update on COMBACTE status and activities Prof. Dr. Marc Bonten (UMC Utrecht) 18:50-19:10 Studies on Clostridium
Is contamination of bronchoscopes really a problem?
Is contamination of bronchoscopes really a problem? 1 Is contamination of bronchoscopes really a problem? High Level Disinfection does not methodically clean bronchoscopes What we know 210 More than 210
Synchrotron Science and Protein Crystallography
Your Brief You will work with your mentors to grow protein crystals and use X-ray diffraction sources to study the crystal structure of lysozyme. You will have an overall view of what it takes to study
Microbial Culture Collection of Cantacuzino Institute
Microbial Culture Collection of Cantacuzino Institute Present and perspectives of development Olguta Dracea, Camelia Babes, Rodica Oancea, Anca Israil, Irina Codita, Adrian Onu, Gabriel Ionescu Cantacuzino
Research and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
COMBACTE-NET. Update on ANTICIPATE Study Vienna, Austria MARIA J.G.T. VEHRESCHILD UNIVERSITY HOSPITAL COLOGNE, GERMANY
COMBACTE-NET Update on ANTICIPATE Study Vienna, Austria MARIA J.G.T. VEHRESCHILD UNIVERSITY HOSPITAL COLOGNE, GERMANY 24.04.2017 WP7 Overview ANTICIPATE clinical study: AssessmeNT of the Incidence of Clostridium
Kloster Seeon Meeting on BACE Proteases in Health and Disease. October 6-8, 2013 in Kloster Seeon, Bavaria, Germany
Kloster Seeon Meeting on BACE Proteases in Health and Disease October 6-8, 2013 in Kloster Seeon, Bavaria, Germany Invited Speakers: Bruce Albala, Eisai Mark Albers, Harvard Medical School Michael Boulton,
Research Xchange Forum 2018
Research Xchange Forum 2018 Insights Translation Solutions Trends and Challenges in Regenerative Medicine & Cell Therapy March 20 21, 2018 Sartorius Goettingen, Germany What to expect Learn about the latest
Strategies to design new antibacterial drugs. Jordi Vila Department of Clinical Microbiology Hospital Clinic, Barcelona
Strategies to design new antibacterial drugs Jordi Vila Department of Clinical Microbiology Hospital Clinic, Barcelona Boucher HW, et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases
Hosted by Paul Webber page 1
A Webber Training Teleclass April 8, 24 Bacterial Typing Methods and Their Value in Infection Control Giles Edwards Consultant Microbiologist Stobhill Hospital, Glasgow, UK Scottish MRSA Reference Laboratory
Opportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
CRE is not the first organism we ve had that has become resistant to antibiotics, so why is it so important? CRE resistance is complex because it can
1 Enterobacteriaceae are a large family of bacteria that are a normal part of a person's digestive system (2). Examples include Escherichia coli and species of the genera Klebsiella, Enterobacter, Serratia,
Università Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations
Immune System. Viruses vs. Bacteria
Immune System Viruses vs. Bacteria Concept Map Section 19-1 Bacteria are classified into the kingdoms of Eubacteria Archaebacteria include a variety of lifestyles such as live in harsh environments such
HOSPITAL DISINFECTION Using AEROS And Huwa-San
DB ECOsystems ltd., 35 BO NESS RD, GRANGEMOUTH, FK3 8AN, SCOTLAND. TEL: (01324) 472919 FAX: (01324) 474002 Email: mailroom@dbecosystems.com WEBSITE www.dbecosystems.com REGISTERED OFFICE OF DB ECOsystems
Investing in the Development & Conservation of New Antibiotic Treatments Global Antibiotic R&D Partnership. Introduction. Dr Manica Balasegaram
Investing in the Development & Conservation of New Antibiotic Treatments Global Antibiotic R&D Partnership Peter Beyer, WHO & Jean-Pierre Paccaud, DNDi 13 November 2015 Introduction Dr Manica Balasegaram
October 29 - November
Les Pensières Veyrier-du-Lac (French Alps) October 29 - November 3 2017 Organized by The Mérieux Foundation and the London School of Hygiene & Tropical Medicine ACDx enhances the knowledge and professional
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
Biotechnology Unit: Viruses
Biotechnology Unit: Viruses What do you see here? What is the cause: bacteria or virus? In the late 1800 s Martinus Beijerinck performed this experiment and saw that something smaller than bacteria was
Course Descriptions. BIOL: Biology. MICB: Microbiology. [1]
![Course Descriptions. BIOL: Biology. MICB: Microbiology. [1]](/thumbs/72/66855241.jpg "Course Descriptions. BIOL: Biology. MICB: Microbiology. [1]")
Course Descriptions BIOL: Biology http://www.calendar.ubc.ca/vancouver/courses.cfm?code=biol [1] BIOL 112 (3) Biology of the Cell The principles of cellular and molecular biology using bacterial and eukaryotic
1st German Phage Symposium October 2017, University of Hohenheim, Stuttgart. Preliminary Program. DAY 1 Monday, 9 October 2017
1st German Phage Symposium 9 11 October 2017,, Stuttgart Registration and Welcome Preliminary Program DAY 1 Monday, 9 October 2017 09:15 Registration 10:00 Introduction to the Symposium Conference Chair:
Frontiers in Infectious Diseases From Bench to Bedside Holiday Inn Ashkelon December 15-17, 2016
The joint fall workshop of ISM and the Israeli Society for Infectious Diseases: Frontiers in Infectious Diseases From Bench to Bedside Holiday Inn Ashkelon December 15-17, 2016 Thursday, December 15, 2016
Etienne Ruppé AP HP, Hôpital Bichat Claude Bernard UMR 1137 IAME
Etienne Ruppé AP HP, Hôpital Bichat Claude Bernard UMR 1137 IAME Disclosures Consultant for DaVolterra and MaaT Pharma Received funds by biomérieux 2 1. The intestinal microbiota 3 16S profiling 16S and
Viruses and Bacteria Notes
Viruses and Bacteria Notes A. Virus Structure: Viruses are in contrast to bacteria. Viruses are (DNA or RNA) enclosed in a coat called a. Also some viruses have a that helps them infect their host. These
Regulatory hurdles and opportunities
Regulatory hurdles and opportunities Professor Roger Finch Nottingham University Hospitals & University of Nottingham, UK Drug licensing and regulation Mandatory for market authorisation Supports the public
Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi
Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi Need for public-private collaboration Challenges of AB
Applications of In Situ Hybridisation in Research and Disease
Cancer Research UK Cambridge Institute Applications of In Situ Hybridisation in Research and Disease 7 8 May 2015 Programme Applications of In Situ Hybridisation in Research and Disease 11 Thursday 7 May
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
LTX 109. BIO International Philadelphia 2015
LTX 109 BIO International Philadelphia 2015 Lytix Biopharma company background Established in 2003 to develop and commercialize medical applications of lytic peptides originating from the University of
Phage therapy. History
Phage therapy From Wikipedia, the free encyclopedia Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections. Bacteriophages, or "phages" are viruses that invade
+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
Supported by an educational grant from Bayer AG, Germany
Supported by an educational grant from Bayer AG, Germany c. Garrard (Ed.) Ciprofloxacin i. v. Defining Its Role in Serious Infections International Symposium, Salzburg, September 1993 Springer-Verlag Berlin
ANAEROBIC DENTAL INFECTIONS AND ADVANCE LABORATORY DIAGNOSIS: A MINI REVIEW
Review Article Biswajit Batabyal,, 2012; Volume 1(5):533-538 ISSN: 2277-8713 ANAEROBIC DENTAL INFECTIONS AND ADVANCE LABORATORY DIAGNOSIS: A MINI REVIEW BISWAJIT BATABYAL 1,SUKANTA CHAKRABORTY 2, SHIBENDU
KEYNOTESPEAKERS. JamesWilson ProfessorofInternalMedicineandPathology& LaboratoryMedicineand DirectoroftheGeneTherapyProgram UniversityofPennsylvania
KEYNOTESPEAKERS RichardGati DistinguishedProfessorofthe DepartmentsofPathology&LaboratoryMedicine andhumangenetics DavidGefenUCLASchoolofMedicine JamesWilson ProfessorofInternalMedicineandPathology& LaboratoryMedicineand
Available online Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(6):95-99 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Antibiotic Resistance Test of CefadroxilAgainst Clinical
Accuracy of bacterial DNA testing for central venous catheter-associated bloodstream infection in children with cancer
Accuracy of bacterial DNA testing for CVC-associated BSI in children with cancer Accuracy of bacterial DNA testing for central venous catheter-associated bloodstream infection in children with cancer M
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
What is Net Present Value and Why is it Killing My Research? Steven J. Projan, PhD DriveAB Septermber 2017 Sept 6, 2017
What is Net Present Value and Why is it Killing My Research? Steven J. Projan, PhD DriveAB Septermber 2017 Sept 6, 2017 Welcome to the Movement! Pierre Meulien: "The Drive AB Movement" is now the time?
DNA The Genetic Material
DNA The Genetic Material 2006-2007 Genes are on chromosomes Morgan s conclusions genes are on chromosomes but is it the protein or the DNA of the chromosomes that are the genes? initially proteins were
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
European Epidemiological Forum
European Epidemiological Forum Observational Research and Pharmacoepidemiology in Europe: deeper insights to drive health research and discovery Amsterdam,The Netherlands Hyatt Place Amsterdam Airport
sirna Overview and Technical Tips
1 sirna Overview and Technical Tips 2 CONTENTS 3 4 5 7 8 10 11 13 14 18 19 20 21 Introduction Applications How Does It Work? Handy Tips Troubleshooting Conclusions Further References Contact Us 3 INTRODUCTION
PLTW Biomedical Science Medical Interventions Course Outline
Follow the fictitious Smith family as you learn about the prevention, diagnosis, and treatment of disease. Play the role of biomedical professionals to analyze case information and diagnose and treat your
Penicillin. Introduction:
Penicillin Introduction: Penicillin is a group of antibiotics derived from Penicillium fungi.penicillin antibiotics are historically significant because they were the first drugs that were effective against
LA SPEZIA NAVY BASE MAY
what Seafuture & Maritime Technologies 2016 is the ideal event to showcase maritime innovation and technology to main contractors in the civil and defence sectors through: advanced bilateral meetings among
LUPAS Luminescent Polymers for in vivo Imaging of Amyloid Signatures
LUPAS Luminescent Polymers for in vivo Imaging of Amyloid Signatures A research project for innovative diagnostics for neurodegenerative disorders Funded by the European Union under the 7 th Framework
Verification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
PURPOSE GENERAL CITY INFORMATION HOST WHAT IS SO SPECIAL ABOUT ITMIG? Torino, Italy
PURPOSE Building on the success of previous meetings, the Conference will feature invited lectures, debates, poster sessions and oral abstract sessions focusing on topics such as paraneoplastic and immune
REIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
MINIREVIEW. Bacteriophage Therapy
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 649 659 Vol. 45, No. 3 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.3.649 659.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
MINIREVIEW. Bacteriophage Therapy
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 649 659 Vol. 45, No. 3 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.3.649 659.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
Silk route to the acceptance and re-implementation of bacteriophage therapy
DOI 10.1002/biot.201600023 Silk route to the acceptance and re-implementation of bacteriophage therapy Expert round table on acceptance and re-implementation of bacteriophage therapy. Supporting information
Partnering ACOs. with Summit. 4th. October 27-28, 2014 Hotel Palomar Los Angeles-Westwood, Los Angeles, CA
4th Partnering ACOs October 27-28, 2014 Hotel Palomar Los Angeles-Westwood, Los Angeles, CA with Summit Improve Patient Outcomes and Reduce Costs While Building Valuable Strategic Cross Industry Collaborations
Brochure. 3 rd International Conference on Applied Microbiology and Beneficial Microbes. June Osaka, Japan. conferenceseries.
conferenceseries.com Brochure 3 rd International Conference on Applied Microbiology and Beneficial Microbes June 6-7 2018 Osaka, Japan Theme: Accumulate, segregate and remodel micro-organisms for upliftment
Research Xchange Forum 2018
Research Xchange Forum 2018 Insights Translation Solutions Trends and Challenges in Regenerative Medicine & Cell Therapy March 20 21, 2018 Sartorius Goettingen, Germany What to expect Learn about the latest
DETECTION OF BACTERIAL BIOFILM IN PATIENTS WITH INDWELLING URINARY CATHETERS
DETECTION OF BACTERIAL BIOFILM IN PATIENTS WITH INDWELLING URINARY CATHETERS *Pallavi Sayal, Kanwardeep Singh and Pushpa Devi Department of Microbiology, Govt. Medical College, Amritsar PIN 143001 *Author
Nanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!
INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! TOPADUR PHARMA AG a promising Swiss start-up investment Global Medical Need: Diabetes mellitus is one of the major health concerns worldwide.
at UniBS Engineering Faculty June, 2011
at UniBS Engineering Faculty June, 2011 The Biomedical Manufacturing Summer School Description A comprehensive program on Biomedical Devices (BMD) applications, design, development and manufacturing. The
7 Sexual Health.
RESE ARCH & DEVELOPMENT 22 Highlights Signed an agreement with Medicines for Malaria Venture (MMV) to provide MMV with access to the Pfizer library of novel chemical entities to screen for compounds that
Utilisation des nanomatériaux en agroalimentaire ; exemple d application pour la branche laitière
Utilisation des nanomatériaux en agroalimentaire ; exemple d application pour la branche laitière Katharina M. Fromm Université de Fribourg 21.09.2017 What we do in the Fromm Group Expertise in nano-structured
Joint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
COST ACTION FA0904 February 26-28, 2014 Rome-Italy. EMANUELE FIORE Scientific Officer Embassy of Italy in Canada 275 Slater Street, Ottawa ON K1P5H9
COST ACTION FA0904 February 26-28, 2014 Rome-Italy EMANUELE FIORE Scientific Officer Embassy of Italy in Canada 275 Slater Street, Ottawa ON K1P5H9 emanuele.fiore@esteri.it emanuele.fiore@cnr.it Universitè